Drug Discovery and Repurposing for monogenic disorders


Drug repurposing allows a reconciliation of the time of research with the one of medicine in order to meet the high medical need of genetic disorders

individualized drug discovery

Individualized screening of thousand molecules helps in identifying drug candidates for the patient ans potential new therapeutic targets.


The development of approved molecule is facilitated by the available knowledge produced by the former developments.

APTEEUS offers individualized research programs tailored to patients with rare monogenic diseases.
APTEEUS wishes to develop its activity and to engage its first drug candidate into a pharmaceutical and clinical development.
APTEEUS has unique technology and know-how for drug discovery on primary cells.

APTEEUS is a biotech expert in drug discovery and repositioning in the field of rare monogenic diseases. We are particularly interested in pathologies whose medical need is significant and largely unmet. Our technology allows us to conduct individualized research projects in a few months and identify new drug candidates among all molecules already used in humans, in collaboration with patient organizations, physicians and academic and industrial partners. Our innovative activity, which is at odds with the traditional drug discovery approach, aims to achieve a rapid and significant social impact.



OPERANDO is the biomedical research program in place for collecting cutaneous biopsies from patients in order to isolate the cells “model” of the pathology.


evidenceFactory is the processes we use to measure, in vitro, the causal defects of the symptoms. Based on cell imaging and mass spectrometry, they are systematically miniaturized and automated to quickly test several thousand molecules.

TEE Library®

TEE Library is our proprietary collection of molecules approved for human use and enriched daily that we test in every new screen.


You will read why we decided to run clinical trials with clofoctol in covid19… Large…

Read more

The entire Apteeus team is delighted with this news. After months of fundraising, designing the…

Read more

“Thanks to a technology based on mass spectrometry, we were able, in less than 10…

Read more


Dr. Terence Beghyn

Pharm.D & PhD in Medicinal Chemistry

Terence co-founded Apteeus after a career as an assistant Professor at the University of Lille. Passionate about drug discovery technologies, he now puts his expertise at the service of patients with orphan diseases. Terence is President of Apteeus.

Professor Benoit DEPREZ

Professor of Pharmacy

Benoit began his career in two biotech companies by leading the chemistry and drug discovery teams. Returning to the University in 2006, he set up a drug discovery laboratory at the Institut Pasteur de Lille, which was labelled by INSERM. Benoit is Scientific Director of the Institut Pasteur de Lille. He co-founded Apteeus and is strategic advisor.